SOURCE: BioMedReports

BioMedReports

December 19, 2011 11:24 ET

Due This Week: Key Phase II-B Clinical Trial Results for Important Smoking Cessation Program

LOS ANGELES, CA--(Marketwire - Dec 19, 2011) - A recent article in the New York Times highlighted the 22nd Century Group (OTCBB: XXII) and the firm's "very low nicotine" tobacco which represents a disruptive technology that could transform the $80 billion US tobacco market as well as the $1 billion smoking cessation industry.

At the moment, however, this innovative microcap remains largely unnoticed by Wall Street. Besides, Elemer Piros, Ph.D., Rodman & Renshaw analyst who covers 22nd Century (with a 12-month price target of $5.00 for the now sub-$1 stock), very few have given XXII much notice. For precisely this reason, 22nd Century is worth a careful look now. Keep in mind the following:

  • Three independent Phase II trials have already demonstrated efficacy of very low nicotine cigarettes for smoking cessation. If the company-sponsored Phase II-B clinical trials that are now underway simply replicate the results of the Hatsukami study, X-22 will be seen as perhaps the most effective smoking cessation aid in the world;
  • No other tobacco or pharmaceutical company in the world can produce tobacco cigarettes at the levels of 22nd Century's VLN tobacco. If the FDA mandates drastically lower nicotine levels in commercial cigarettes -- or if 22nd Century is authorized to market its cigarettes as "Modified Risk" -- the company will have massive licensing opportunities domestically and world-wide;
  • XXII is already generating revenue. Operating losses are minimal. Based on 22nd Century's reported revenue for the nine months ended September 30, 2011 totaling $1.02 million, including net sales of $802 thousand, and de minimis Q3 quarter net loss of only $.02/share, the company is well on its way to commercializing its high margin products.

Late this week, investors in XXII can look forward to seeing results in the company's Phase II-B clinical trial which should be followed by the likely filing for fast track status for their X-22 prescription smoking aid with the FDA. In 2012, the company expects to continue its sales of SPECTRUM government research cigarettes, begin marketing "Nicotine-Free" and "High Nicotine/Low Tar" safer cigarettes internationally, and will expand distribution of its super-premium RED SUN cigarettes in the U.S. Each of these initiatives represents substantial sales potential.

At today's market cap of just $28 million, there is plenty of headroom for this undiscovered stock to run.

A full stock research report, including some of the catalysts investors should be looking for in 2012 as far as the 22nd Century Group is concerned, is available now at:

http://www.biomedreports.com/2011121986049/key-clinical-trial-results-await-emerging-player-in-the-smoking-cessation-industry-this-week.html

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556